Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab

BACKGROUND: We hypothesized that elevations of plasma Oncostatin M (OSM) would be associated with infliximab nonresponse. METHODS: Plasma OSM was measured in Crohn disease patients pre-infliximab with biochemical response (>50% reduction in fecal calprotectin) as the primary outcome. RESULTS: The...

Descripción completa

Detalles Bibliográficos
Autores principales: Minar, Phillip, Lehn, Christina, Tsai, Yi-Ting, Jackson, Kimberly, Rosen, Michael J, Denson, Lee A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Observations And Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798793/
https://www.ncbi.nlm.nih.gov/pubmed/31667468
http://dx.doi.org/10.1093/crocol/otz026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798793/
https://www.ncbi.nlm.nih.gov/pubmed/31667468
http://dx.doi.org/10.1093/crocol/otz026

Ejemplares similares